{"id":"brexpiprazole-opc-34712","safety":{"commonSideEffects":[{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Sedation/somnolence"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a partial agonist at D2 receptors, brexpiprazole provides dopaminergic stabilization with lower intrinsic activity than full agonists, reducing the risk of excessive dopamine stimulation. Its 5-HT1A partial agonism and 5-HT2A antagonism contribute to anxiolytic and antidepressant-like effects. This multi-target profile is designed to provide antipsychotic efficacy with improved tolerability compared to first-generation antipsychotics.","oneSentence":"Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors while antagonizing serotonin 5-HT2A receptors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:25.253Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Schizoaffective disorder"},{"name":"Major depressive disorder (adjunctive treatment)"}]},"trialDetails":[{"nctId":"NCT03238326","phase":"PHASE3","title":"Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2017-08-23","conditions":"Schizophrenia","enrollment":295},{"nctId":"NCT04174365","phase":"PHASE3","title":"Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2019-10-30","conditions":"Irritability Associated With Autism Spectrum Disorder (ASD)","enrollment":119},{"nctId":"NCT03620981","phase":"PHASE2, PHASE3","title":"Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2018-08-20","conditions":"Agitation Associated With Dementia of the Alzheimer's Type","enrollment":410},{"nctId":"NCT04186403","phase":"PHASE2, PHASE3","title":"Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2020-01-13","conditions":"Borderline Personality Disorder","enrollment":201},{"nctId":"NCT03724942","phase":"PHASE3","title":"Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2018-11-09","conditions":"Agitation Associated With Dementia of the Alzheimer's Type","enrollment":164},{"nctId":"NCT04258839","phase":"PHASE3","title":"Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2020-01-23","conditions":"Irritability Associated With Autism Spectrum Disorder","enrollment":95},{"nctId":"NCT04830215","phase":"PHASE4","title":"Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2021-04-01","conditions":"Major Depressive Disorder","enrollment":122},{"nctId":"NCT03198078","phase":"PHASE3","title":"Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2017-06-30","conditions":"Schizophrenia","enrollment":316},{"nctId":"NCT03538691","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-07-13","conditions":"Major Depressive Disorder","enrollment":1149},{"nctId":"NCT03548584","phase":"PHASE3","title":"A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-05-16","conditions":"Agitation Associated With Alzheimer's Dementia, Alzheimer Dementia","enrollment":345},{"nctId":"NCT01074294","phase":"PHASE2","title":"Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-03-16","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":740},{"nctId":"NCT03033069","phase":"PHASE2","title":"A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2017-01-26","conditions":"Stress Disorders, Post-Traumatic","enrollment":336},{"nctId":"NCT03902574","phase":"PHASE1","title":"Bioequivalence Study of Brexpiprazole Orally Disintegrating Tablets (ODT) 2mg","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2019-03-27","conditions":"Healthy Adult Male","enrollment":21},{"nctId":"NCT02875080","phase":"PHASE1","title":"Evaluation Study of the Bioavailability of Brexpiprazole Orally Disintegrating Tablets in Healthy Male Subjects","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2016-09-27","conditions":"Healthy Adult Male","enrollment":18},{"nctId":"NCT01862640","phase":"PHASE3","title":"A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2013-07-11","conditions":"Agitation Associated With, Alzheimer's Disease, Alzheimer's Type","enrollment":433},{"nctId":"NCT01922258","phase":"PHASE3","title":"Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2013-09","conditions":"Agitation Associated With, Alzheimer's Disease, Alzheimer's Type","enrollment":270},{"nctId":"NCT03287869","phase":"PHASE3","title":"A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2017-10-24","conditions":"Bipolar I Disorder, Acute Mania","enrollment":381},{"nctId":"NCT02194933","phase":"PHASE3","title":"Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2015-02","conditions":"Schizophrenia With Impulsivity","enrollment":38},{"nctId":"NCT01360866","phase":"PHASE3","title":"Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-10","conditions":"Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":2944},{"nctId":"NCT02196506","phase":"PHASE3","title":"Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2014-07","conditions":"Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":837},{"nctId":"NCT03292848","phase":"PHASE1","title":"Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2017-10-10","conditions":"ADHD, Autism, Bipolar I Disorder","enrollment":24},{"nctId":"NCT01727726","phase":"PHASE3","title":"A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2012-12","conditions":"Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":2182},{"nctId":"NCT02192554","phase":"","title":"Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2014-06","conditions":"Agitation Associated With Alzheimer's Disease, Alzheimer's Type, Mental Disorder","enrollment":450},{"nctId":"NCT02411695","phase":"PHASE1","title":"Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2015-03","conditions":"Schizophrenia","enrollment":40},{"nctId":"NCT01668797","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2012-10","conditions":"Acute Schizophrenia","enrollment":524},{"nctId":"NCT02212613","phase":"PHASE3","title":"Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability","status":"WITHDRAWN","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2014-09","conditions":"Major Depressive Disorder and Irritability","enrollment":""},{"nctId":"NCT02013609","phase":"PHASE3","title":"Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2013-11","conditions":"MDD","enrollment":48},{"nctId":"NCT02013622","phase":"PHASE3","title":"Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2013-11","conditions":"Schizophrenia","enrollment":49},{"nctId":"NCT02013531","phase":"PHASE3","title":"Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2013-11","conditions":"Major Depressive Disorder, Anxiety","enrollment":37},{"nctId":"NCT00797966","phase":"PHASE2","title":"Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":850},{"nctId":"NCT01360632","phase":"PHASE3","title":"Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-06","conditions":"Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":1539},{"nctId":"NCT02054702","phase":"PHASE3","title":"Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2014-02","conditions":"Schizophrenia","enrollment":97},{"nctId":"NCT01360645","phase":"PHASE3","title":"Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-07","conditions":"Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":826},{"nctId":"NCT01396421","phase":"PHASE3","title":"Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-07","conditions":"Acute Schizophrenia","enrollment":636}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Brexpiprazole (OPC-34712)","genericName":"Brexpiprazole (OPC-34712)","companyName":"Otsuka Pharmaceutical Development & Commercialization, Inc.","companyId":"otsuka-pharmaceutical-development-commercialization-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors while antagonizing serotonin 5-HT2A receptors. Used for Schizophrenia, Schizoaffective disorder, Major depressive disorder (adjunctive treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}